Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PC-3M |
Human prostate carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. L. Omara-Opyene et al., Lab Invest., 2004 Jul; 84(7):894-907 | |||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | U. Weirauch et al., Nucleic Acid Therapeutics, 2013, 23 (4): 264-272, DOI: 10.1089/nat.2012.0407 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | U. K. Mukhopadhyay et al., Cancer Res., Apr 2005; 65: 2872 - 2881 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | U. K. Mukhopadhyay et al., Cancer Res., Apr 2005; 65: 2872 - 2881 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Endres et al., Oncotarget, 2016, 7(39): 64244-64259 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | K. S. R. Sastry et al., J. Biol. Chem., Jul 2006; 281: 20891 - 20901 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | T. Sugawara et al., J. Biol. Chem., Oct 2003; 278: 42487 - 42494 | Link | ||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Wang et al., Am. .J Transl. Res., 2012, 4 (4): 390-402 | Link | ||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | D. Fu et al., Endocr. Relat. Cancer, Mar 2014; 21: 297 - 310 | Link | ||
HeLa-fLuc |
Human cervix adenocarcinoma cell line, stably expressing Firefly-Luciferase (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-eGFP |
Human cervix adenocarcinoma cell line, stably expressing eGFP (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-DR-13–9 |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | B. Haynesa et al., Biochim Biophys Acta Mol Basis Dis., 2020,1866(1): 165561, doi:10.1016/j.bbadis | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | X. M. M. Weyel, Dissertation, 2018, Goethe- Universität in Frankfurt am Main | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | J. H. Kim et al., J. Biol. Chem., Jun 2006; 281: 15747 - 15756 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | V. Mikat et al., RNA, Dec 2007; 13: 2341 - 2347 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | C. T. Hellwig et al., J. Biol. Chem., Aug 2008; 283: 21676 - 21685 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Pagano et al., 2014, US 8,778,905 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | K. J. Choi et al., Cancer Res., Apr 2007; 67: 3654 - 3662 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | L. T. Jennelle, Dissertation, 2013, George Washington University | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Benincá et al., J. Med. Genet., 2021, 58: 155–167, doi:10.1136/jmedgenet-2020-106861 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. G. Theis et al., PNAS, Aug 2004; 101: 11221 - 11226 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | L. Jennelle et al., J. Biol. Chem., Oct 2014; 289: 28870 - 28884. |